HEL4 domain fragment & Anti CD20 mAb process specification report

A process specification report will be prepared detailing the optimised upstream production and conventional downstream purification procedures for anti-CD20 mAb and HEL4 VH domain fragment. This will include details of the analytical methods developed to characterise the material at each of the three purity levels (post-harvest, post-capture column and final product) and the baseline quality attributes generated from these methods to allow for comparison with the crystallization process.